Navigation Links
FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors
Date:4/15/2011

l recurrent GBM patients in the US."

"The FDA approval of the NovoTTF device is the culmination of ten years of research, development and clinical trials conducted by an exceptional team of scientists, engineers, and clinicians and built on the original insights of our founder and CTO Yoram Palti, M.D., Ph.D." said William F. Doyle, Novocure's executive chairman. "We look forward to bringing this device to recurrent GBM patients and their families, and we look forward to developing NovoTTF therapy for a range of additional solid tumor cancers."

Pivotal Trial Results

The FDA approval was based on data from a randomized pivotal trial of 237 patients with glioblastoma tumors that had recurred or progressed despite previous surgical, radiation and chemotherapy treatments. Patients treated with the NovoTTF alone achieved a comparable overall survival time to patients treated with the physician's choice of the best chemotherapy. The rate of progression free survival at six months (PFS6) was 21% in the NovoTTF group compared to 15% in chemotherapy patients. Also, patients treated with the NovoTTF had a 14% tumor response rate (RR) compared to 10% in chemotherapy treated patients in the trial, and 3 complete radiographic responses were observed in the NovoTTF group compared to none in chemotherapy patients. NovoTTF treated patients reported better quality of life scores and fewer side effects during the trial compared to patients treated with chemotherapy. Specifically, quality of life using the device was better than that of chemotherapy patients in the following subscale domains: vomiting, nausea, pain, diarrhea, constipation, cognitive functioning and emotional functioning, all of which are hallmarks of patient suffering while receiving chemotherapy. The most commonly reported side effect from NovoTTF treatment was a mild-to-moderate rash beneath the electrodes.


'/>"/>

Contact: Frank Leonard
frank@novo-cure.com
917-656-3518
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado
2. DFG approves 12 new collaborative research centers
3. DFG approves funding for 17 new collaborative research centers
4. Death -- not just life -- important link in marine ecosystems
5. Stress wrecks intestinal bacteria, could keep immune system on idle
6. Common nanoparticles found to be highly toxic to Arctic ecosystem
7. A better understanding of the aging immune system
8. E. coli an unlikely contaminant of plant vascular systems
9. Human impacts on the marine ecosystems of Antarctica
10. A new signaling pathway of the immune system is elucidated
11. MIT systems biologists use computer models to predict animal cell behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Ecology drives evolution. In today,s issue of the journal ... growing evidence that the reverse is also true, and ... how environmental change affects species and vice-versa. A ... a Galpagos ground finch, Geospiza fortis. In this species, ...
... available in French . , Montreal, January 28, 2011 ... a rare form of cancer that caused a strange combination of ... his stomach and colon. His medical team was stumped and was ... family: the cause of his disease and the risk for future ...
... University of the Negev (BGU) and the PTT Chemical ... research and development collaboration agreement for commercial development of ... for the production of dihomo gamma-linolenic acid (DGLA- Omega ... Parietochloris incise. The joint research will focus on optimizing ...
Cached Biology News:Cold cases gone hot: Montreal researchers solve decades-old medical mysteries using genetics 2Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain 2
(Date:4/16/2015)... (PRWEB) April 16, 2015 Proove ... Buzz of BIO Contest for the 2015 ... (BIO), the 2015 BIO International Convention will take place ... Pennsylvania. During the Buzz of BIO contest, industry leaders ... see present at the conference. The community voting period ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... PARK, N.C., Jan. 14, 2011 Talecris Biotherapeutics Holdings Corp. ... established a new record date and meeting date for the ... merger agreement under which Grifols (GRF.MC) will acquire TLCR. ... on January 11, 2011 will be entitled to vote at ...
... now open for StemCONN 2011. The full-day ... cell research, will take place Tuesday, March 22, in ... the UConn Health Center (commercial session and tour). ... http://stemconn.org/ . StemCONN 2011 will feature a ...
... reversal of tinnitus, a debilitating hearing impairment affecting at ... 40 percent of military veterans, according to an article ... Nature . Researchers Dr. Michael Kilgard and ... Dallas and University-affiliated biotechnology firm MicroTransponder report that stimulation ...
Cached Biology Technology:Nature article focuses on tinnitus treatment 2Nature article focuses on tinnitus treatment 3
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: